Navigation Links
Capricor Therapeutics Announces the First Patient with Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated with CAP-1002 in the HOPE-Duchenne Phase I/II Clinical Trial
Date:2/22/2016

LOS ANGELES, Feb. 22, 2016 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced continuing enrollment of, and the treatment of the first patient with Duchenne Muscular Dystrophy (DMD)-related cardiomyopathy with CAP-1002 in the HOPE-Duchenne Phase I/II clinical trial (Halt cardiomyOPathy progrEssion in Duchenne). CAP-1002 is Capricor's allogeneic, cardiosphere-derived stem cell (CDC) therapy. The patient was treated at the Cincinnati Children's Hospital Medical Center under the direction of Dr. John Jefferies, the national principal investigator for the HOPE-Duchenne trial. Enrollment is now ongoing at Cincinnati Children's Hospital Medical Center in Cincinnati, Ohio and at Cedars-Sinai Heart Institute in Los Angeles, California.

The HOPE-Duchenne trial is designed to enroll 24 patients in a randomized, multi-center study evaluating the safety and efficacy of CAP-1002. Patients randomized to receive the cells will receive CAP-1002 in all three coronary arteries which will enable delivery extensively across the myocardium. Improvement in cardiac function was recently reported using this approach in Capricor's DYNAMIC trial for adult patients with Class III Heart Failure. Cardiomyopathy is currently the leading cause of death in patients with DMD now that other treatments are available to mitigate other aspects of the disease process.

"DMD is a genetic disorder characterized by progressive muscle deterioration. Patients with DMD also develop cardiopulmonary dysfunction in their teen years with death often occurring in their twenties," said John L. Jefferies, M.D., MPH, FAAP, FACC, Professor, Pediatric Cardiology and Adult Cardiovascular Diseases, University of Cincinnati College of Medicine, and Director, Advanced Heart Failure and Cardiomyopathy, Cincinnati Children's Hospital Medical Center. "Based on Capricor's prior encouraging clinical experience with CDC cell therapy in adults who have either suffered a heart attack or have heart failure, supplemented by the positive data in the mouse pre-clinical model of DMD (mdx), we are pleased to be able to begin the HOPE trial in boys and young men with DMD. Scarring is the hallmark of DMD cardiomyopathy and as the patients get older, the scar quantity expands and cardiac function then deteriorates. CDCs have been shown clinically in both the CADUCEUS and ALLSTAR Phase I clinical trials to reduce scar in the heart which might also benefit boys with DMD cardiomyopathy. We are happy to report that our first patient in the trial tolerated the CAP-1002 infusion procedure extremely well."

"We are thrilled to have initiated the HOPE-Duchenne clinical trial," said Linda Marbán, Ph.D., Chief Executive Officer of Capricor. "CAP-1002 is to our knowledge the only clinical stage therapy intended to reduce fibrosis and scar in hearts affected by DMD. One of our goals with our CDCs is to target orphan diseases with cardiac implications, and DMD cardiomyopathy is our first target along these lines. We are hopeful that CAP-1002 may be a big step forward as a treatment option for DMD cardiomyopathy which at present is a progressive disease with poor therapeutic options."

For more information, please visit: http://capricor.com/hope/ or ClinicalTrials.gov (NCT02485938).

About Duchenne Muscular Dystrophy (DMD) 
DMD afflicts approximately 20,000 boys and young men in the USA. The central cause is a genetic abnormality in the dystrophin complex, leading to membrane fragility with secondary damage to skeletal and cardiac muscle. No treatment has been proven effective for DMD; patients usually die in young adulthood. Various clinical trials are ongoing, but almost all target the skeletal myopathy. Much of the death and disability in the later years of DMD is due to heart disease rather than to skeletal muscle disease. Virtually all DMD patients aged >15 years develop heart failure, and mortality is high despite optimal medical therapy. Heart transplantation is not typically an option for DMD patients.

About CAP-1002
CAP-1002, Capricor's lead product candidate, is a proprietary allogeneic adult stem cell therapy for the treatment of heart disease. The product is derived from donor heart tissue. The cells are expanded in the laboratory using a specialized process and then introduced directly into a patient's heart via infusion into a coronary artery using standard cardiac catheterization techniques. CAP-1002 is currently not an approved product and is strictly for investigational purposes.

About Capricor Therapeutics 
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics. The Company's lead programs target post myocardial infarction (heart attack), heart failure and Duchenne Muscular Dystrophy. The Company has two lead product candidates under investigation: CAP-1002, a cardiac cell therapy, and Cenderitide, a natriuretic peptide receptor agonist. CAP-1002 is in development for the treatment of post myocardial infarction, advanced heart failure and Duchenne muscular dystrophy-associated cardiomyopathy. Cenderitide is in development for the outpatient treatment of heart failure as well as potential other indications. In addition, the Company is conducting research and development on its exosomes platform technology for cardiac diseases and other potential indications. For additional information, visit www.capricor.com.

Cautionary Note Regarding Forward-Looking Statements 
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the conduct, size, timing and results of discovery efforts and clinical trials; plans regarding regulatory filings, future research and clinical trials; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business are set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission on March 16, 2015, in its Registration Statement on Form S-3, as filed with the Securities and Exchange Commission on September 28, 2015, and in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, as filed with the Securities and Exchange Commission on November 13, 2015. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

For more information, please contact:

Corporate Contact
Capricor Therapeutics, Inc.
AJ Bergmann, Vice President of Finance 
+1-310-358-3201
abergmann@capricor.com 

Investor Relations:
Argot Partners 
Angeli Kolhatkar
+1-212-600-1902
angeli@argotpartners.com

 


'/>"/>
SOURCE Capricor Therapeutics, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Capricor Therapeutics Reports Third Quarter 2015 Business & Financial Highlights
2. Cryoport Expands Logistics Support to Capricors DYNAMIC Clinical Trial for Heart Failure
3. Mast Therapeutics Completes Patient Enrollment In Pivotal Phase 3 "EPIC" Study For The Treatment Of Sickle Cell Crisis
4. eFFECTOR Therapeutics Increases its Series B Financing Round to $56M
5. Mast Therapeutics Closes $8 Million Public Offering
6. Capsugel and Pulmatrix Enter Collaboration to Develop and Manufacture Novel Inhaled Therapeutics
7. ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University to Advance Stem-to-T-Cell Program
8. Ennaid Therapeutics Prioritizes Zika Virus Rapid Drug Development in Wake of Crisis
9. Telesta Therapeutics veröffentlicht Geschäftsbericht des 2. Quartals 2016 sowie aktuelle Meldungen zum Unternehmen
10. Chronic Inflammation Market H2 2015 Clinical Trials Review and Therapeutics Development
11. Lonza and Renova Therapeutics Announce Manufacturing Agreement for Clinical Supply of RT-100 Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2018)... COAST, Queensland (PRWEB) , ... October 16, 2018 , ... ... menu, including mocha body scrubs, handmade green clay facials and peppermint foot soaks to ... Saoirse, owner of Ripple Massage. , “We feel our clients still want all the ...
(Date:10/16/2018)... ... October 16, 2018 , ... The iaedp™ ... multidisciplinary group of healthcare treatment providers who treat the full spectrum of eating ... a live, two-day, 12-hour track at Symposium 2019. The courses are regularly ...
(Date:10/13/2018)... ... October 12, 2018 , ... David ... 1987 which was used in the Lockheed F22 Aircraft. Today, he announces the ... uncontrolled AF-Arrhythmia, which can lead to sudden cardiac death (SCD). , The Two-Dimensional ...
Breaking Medicine Technology:
(Date:10/18/2018)... (PRWEB) , ... October 18, ... ... the publication of a research study demonstrating the company’s automated preclinical image ... for optical imaging systems. The technology finds applications in preclinical imaging of ...
(Date:10/17/2018)... (PRWEB) , ... October 17, 2018 , ... The Jacobs ... the California Association of Food Banks at a meeting of its Board of Directors. ... food banks across the State of California. CAFB provides its member food banks with ...
(Date:10/17/2018)... Calif. (PRWEB) , ... October 17, 2018 , ... The Myers’ have been ... p.m. at their office, 11141 Tampa Ave., Northridge, CA 91326. , “The Harvest Festival ... at the same time help the kids at Children’s Hospital LA,” said Kris and Keith. ...
(Date:10/16/2018)... ... October 16, 2018 , ... Balboa Capital , ... and franchise financing , is now recognized by Massage Envy as an ... structure and deliver custom-tailored financing programs to Massage Envy franchisees who need funding ...
(Date:10/16/2018)... ... October 16, 2018 , ... ... recipient of the Academy of Integrative Health and Medicine’s (AIHM) Visionary Award for ... medicine. , Dr. Pizzorno was selected as AIHM’s recipient of the Visionary ...
Breaking Medicine News(10 mins):